Abstract
In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1037-1043 |
| Number of pages | 7 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 59 |
| Issue number | 6 |
| State | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis. / Sakhaee, K.; Nicar, M. J.; Glass, K.; Zerwekh, J. E.; Pak, C. Y.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 59, No. 6, 1984, p. 1037-1043.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis
AU - Sakhaee, K.
AU - Nicar, M. J.
AU - Glass, K.
AU - Zerwekh, J. E.
AU - Pak, C. Y.
PY - 1984
Y1 - 1984
N2 - In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.
AB - In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.
UR - http://www.scopus.com/inward/record.url?scp=0021686268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021686268&partnerID=8YFLogxK
M3 - Article
C2 - 6490791
AN - SCOPUS:0021686268
VL - 59
SP - 1037
EP - 1043
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 6
ER -